scPharmaceuticals Q3 2021 Earnings Report
Key Takeaways
scPharmaceuticals reported a net loss of $6.6 million for the third quarter of 2021 and ended the quarter with $85.0 million in cash, cash equivalents, restricted cash and investments. The FUROSCIX NDA resubmission is planned for Q1 2022.
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date.
FUROSCIX® NDA resubmission anticipated for Q1 2022 due to COVID-19 related global supply chain logistics interruptions and travel restrictions.
Ended Q3 with cash, cash equivalents, restricted cash and investments of $85.0 million, sufficient to fund operations into 2023.
Lowered 2021 net loss guidance to $29.0 to $31.0 million.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
The Company expects a net loss for 2021 to be in the range of $29.0 to $31.0 million for the fiscal year.